Skip to main content

All industries

2087 results for All industries
Filters
Refine your search
Manufacturer
Brand Name
CLEAR ALL
A. Costantino & C. S.P.A
Malt extract designed for pharmaceutical preparations. It is an excipient and can be used for pet-food applications. Shelf life: 5 years. Benefits:
  • Vegetal proteins, soluble in water
  • Gives a clear solution
  • Nanoparticles and GMO-free
  • TSE/BSE contamination free
A. Costantino & C. S.P.A
Protease designed for pharmaceutical preparations. It is suitable for in-vitro cell testing and parasite detection. Shelf life: 30 months. Benefits:
  • Nanoparticles and GMO-free
  • Shows activity in acid environments between 37°C and 42°C
  • Proteolytic Activity 1:10000 NF/USP = 2000-2200 U/g FIP
  • TSE/BSE…
A. Costantino & C. S.P.A
Peptone designed for pharmaceutical applications. It is a desiccated liver powder from Italian pork liver. Shelf life: 3 years. Benefits:
  • Mask unpleasant taste
  • Improves palatability of the final product
  • Nanoparticles and GMO-free
  • TSE/BSE contamination free
A. Costantino & C. S.P.A
Peptone designed for pharmaceutical preparations. It is a liver powder from chicken liver. Shelf life: 3 years. Benefits:
  • Mask unpleasant taste
  • Improves palatability of the final product
  • Nanoparticles and GMO-free
  • TSE/BSE contamination free
Actylis
Solvent/co-solvent for pharmaceutical injectable formulations. It has a strong control on all possible impurities along with ICH Q3D compliance for R&D to commercial manufacturing.Benefits:
  • It maintains low level of endotoxins with the bioburden limits- BET/MLT
  • Controlled metallic impurities
  •  Developed for…
Actylis
Antioxidant for pharmaceutical applications such as solid and semi-solid dosage forms.Benefits:
  • DMF filed excipient - CDE # F20200000188
  • All peak positions are within 5cm-1cm of those determined for 3-tert-Butyl-4-hydroxyanisole standard
Actylis
Excipient for pharmaceutical applications such as solid and semi-solid dosage forms.Benefits:
  • DMF filed excipient - CDE # F20200000188
  • All peak positions are within 5cm-1cm of those determined for 3-tert-Butyl-4-hydroxyanisole standard
Actylis
Excipient specially developed for solid and semi-solid dosage forms. It is an antioxidant and reducing agent used in injectable formulations.Benefits:
  • Maintains low level of endotoxins with the bioburden limits (BET/MLT etc)
  • DMF Filed - CDE # F20200000189
Actylis
Bulking agent and antioxidant specially developed for solid and semi-solid dosage forms.Benefits:
  • pH adjustment
  • Clear and colorless or not more intensely colored than reference solution Y7, BY7 or GY7
Actylis
Preservative specially developed for injectable formulations, solid and semi-solid dosage forms.Benefits:
  • DMF Filed
  • Maintains low level of endotoxins with the bioburden limits (BET/MLT etc) 
Actylis
Excipient for use in pharmaceutical applications.Benefits:
  • Acts as a preservative
Actylis
Excipient for pharmaceutical applications.Benefits:
  • Effloresces in warm, dry air. Its solutions are alkaline to phenolphthalein TS, a 0.1 M solution having a pH of about 9
  • Freely soluble in water, very slightly soluble in alcohol
Actylis
Excipient recommended for pharmaceutical applications.
Actylis
Coating agent developed for solid and semi-solid dosage forms.Benefits:
  • Strong control on all possible impurities along with ICH Q3D compliance for R&D to commercial manufacturing
Actylis
Excipient for use in pharmaceutical applications.
Actylis
Solvent/ Co-solvent developed exclusively for use in injectable formulations.Benefits:
  • Maintains low level of endotoxins with the bioburden limits (BET/MLT etc)
  • DMF Filed - CDE # F20190000639